This volume draws together 33 previously published articles (from 1987-2011) on the economics of the pharmaceutical industry. Drug development, economics, and other researchers from the US, Canada, and Europe discuss the structure of the industry, focusing on mergers and acquisitions; patented pharmaceuticals and innovation, including competition in research and development, the cost of innovation, the relationship between firm size and research productivity, the link between gross profitability and pharmaceutical research and development spending, returns on research and development during the 1990s, the effect of Medicare Part D on prices and utilization, and statistics on new drug development; the generic drug industry, including patent expiration, entry, and competition, competition between generic and branded drugs, and entry decisions and pricing; and biologics and biosimilars. Other sections contain articles on the demand for pharmaceuticals, with discussion of how cost sharing affects demand for medical services, the impact of Medicare Part D on prescription drug use by the elderly, the demand effects of changes in prescription drug promotion, de-regulating direct-to-consumer marketing of prescription drugs, and common pharmacoeconomic models, modeling approaches, and methods; pricing, including determinants, strategic pricing, price dynamics, cross-national differences, and pricing in poor vs. wealthy countries; and regulation, with discussion of the Food, Drug, and Cosmetic Act of 1938, consumption externalities and diffusion for antiulcer drugs, price and welfare effects of pharmaceutical substitution reform in Sweden, UK regulations, and the timing of drug approvals in the US and abroad. Annotation ⓒ2014 Ringgold, Inc., Portland, OR (protoview.com)